I am a
Home I AM A Search Login

Papers of the Week

Papers: 22 Oct 2022 - 28 Oct 2022

Human Studies

2022 Oct 21

Dermatol Ther

Baricitinib 2 mg for the treatment of atopic dermatitis in North America: Long-term efficacy and patient-reported outcomes.


Simpson E, Armstrong A, Boguniewicz M, Chiesa Fuxench ZC, Feely M, Pierce E, Sun L, Chen Y-F, Angle R, Silverberg JI
Dermatol Ther. 2022 Oct 21:e15954.
PMID: 36270978.


To address the need for long-term efficacy and patient-reported outcomes (PROs) data for patients with atopic dermatitis (AD) treated with baricitinib 2 mg, a study was conducted to evaluate the efficacy of baricitinib 2 mg in adult patients with moderate-to-severe AD. Data presented here provided efficacy and outcomes data for patients treated for 52 weeks.